351 ‒ Male fertility: optimizing reproductive health, treating infertility, & navigating TRT

The guest, Paul Turek, cited a New England Journal of Medicine study that analyzed diaries from ~700 couples. When sex was timed to ovulation (day 15), only ~20% of conceptions occurred that way. The highest pregnancy rates came from sex on days 9‑13, with every‑other‑day intervals. Even sex 5 days before ovulation produced pregnancies. He emphasized that most apps now tell women to front‑load, yet many still react to the ovulation kit. He also noted that the “pot of soup” in the epididymis contains about half a billion sperm, and most men need 1‑2 days to recharge, so daily ejaculation may lower counts slightly but is usually fine.

Turek published the hot‑bath study in the Brazilian Journal of Urology after American journals refused because they thought the effect was already known. He took infertile men with low sperm counts who were regular hot‑tub users and simply asked them to stop. Total motile sperm count went up 300 % at 3‑4 months and 600 % at 6 months. He then calculated a “lethal dose 50”: 20 minutes at 104 °F, three times a week, would likely bring sperm to zero. He noted that the largest group in his study was environmental lawyers. He now regards hot‑tub history as a first‑line question and advises complete cessation. Saunas are still a concern but much less potent; he estimates the risk at one‑quarter to one‑third that of a hot bath.

Turek explains that varicocele appears at puberty because the left renal vein has no valves and the erect posture creates a hydraulic column. On exam, the left testis is often smaller, and the scrotum feels like a “bag of worms.” He published a study showing that men who had both a varicocele and a Y‑chromosome microdeletion did not improve after repair, whereas those without the deletion did well. He performs the microsurgical repair under twilight sedation, preserving muscle and lymphatics for faster recovery. He notes that ultrasound is not necessary—palpation by an experienced urologist suffices.

Turek built this protocol from years of notes on bodybuilders who cycled steroids. He published a blog called “getting off the juice.” He emphasizes that tapering prevents the “flu‑like” crash that makes men give up. He checks testosterone at the 2‑week‑off nadir: if it’s already in a normal range, prognosis is good. Most men recover sperm within 3‑6 months. He shared a case of a man who used testosterone for 25 years: after aggressive gonadotropin therapy, only a few sperm were retrievable via testicular mapping—enough for IVF. He also describes a “dual therapy” approach for men who won’t stop TRT: adding hCG 250‑500 IU twice weekly while on testosterone, but it requires 100% compliance; missing doses collapses sperm to zero.

Turek recounted a Finnish bodybuilder study where men on huge steroid cycles added 500 IU hCG twice weekly and maintained normal sperm counts throughout 12 weeks. He stressed that many men believe they can take testosterone and “some hCG” and keep fertility, unaware that even 80% compliance leads to zero sperm. He described a patient who stayed on testosterone for 10 years due to primary testicular failure; after 6 months on hCG, they added low‑dose testosterone gel and lowered hCG to 500 twice weekly, and a testicular sperm retrieval yielded plenty of sperm. The key message: only 100% compliance with dual therapy preserves ongoing fertility.

Turek sits on the board of Legacy and advocates sperm banking as the lowest‑hanging fruit in fertility preservation. He started a nonprofit, Banking on the Future, to provide free banking to 16‑21‑year‑olds with cancer. He notes that paternal age risks follow a hockey‑stick curve: a slow linear increase from 25 to 60, then a logarithmic spike. Unlike maternal age risks (which are chromosomal and often screened with PGT‑A), paternal risks are single‑gene mutations and epigenetic changes that aren’t detectable by embryo biopsy—they tend to be neurodevelopmental. He shared his own unease while writing a paper on these risks while having a second child at 50. He also clarified numbers: 3 ejaculates suffice for IUI, 10 give vast IVF capacity. Even azoospermic cancer survivors can often father children with IVF if a few sperm are present in the banked sample.

Turek described a study where men went from moderate exercise to 2 h/day at >80% VO2max for 12 weeks: sperm count fell 40%, testosterone 50%, and reversed when they returned to moderate. Military studies of ‘hell weeks’ showed similar 50% drops in testosterone and LH. He stressed that modern life—constant connectivity, sleep deprivation—creates chronic sympathetic activation. He advocates physical activity as the best stress‑relief for men (running, surfing, etc.). Regarding marijuana, he notes that the active compounds linger in fat for 3‑4 weeks, producing a low‑level toxicity even after the high fades. Two epidemiologic studies 10 years apart link chronic pot use to testicular cancer, which worries him. He also mentioned that cycling saddles with a nose can compress the pudendal nerve and cause numbness, but that’s an erectile issue, not a fertility one.

Turek compares the semen analysis to a poker hand where each card (volume, count, motility, morphology) has specific meaning. He explained the min‑max curve: count peaks after longer abstinence, but motility declines; 3 days is the sweet spot. He advises two analyses at least 3 weeks apart because any single parameter can vary 50‑100%. He often uses a hand‑performed analysis (rather than CASA machines) because observations about homogeneous morphology can reveal rare syndromes. He also emphasized that the semen analysis is a blunt instrument for fertility unless it’s zero.

The guest explains that after ejaculation sperm must traverse an acidic vagina (pH 5) and a cervix lined with a mucus plug that thins only ~2 days per month. Once inside the uterus, the immune system demolishes the first round of sperm like a Roman failance. The sperm secrete FCR receptors that bind antibodies, exhausting the immune response. A second and maybe third wave does the same, and eventually a later wave slips through. This explains why so many sperm are needed—not because they won’t ask for directions, but because most are kamikaze escorts. Eric’s Biosciences (the guest consults for them) is developing an assay to measure this failance cycle, which may explain unexplained infertility. The guest calls it a “sperm cycle” akin to ovulation—a ~90‑minute window where sperm deactivate the local immune system; if the ejaculate lacks this ability, the woman’s defenses stay active and conception fails.

The guest, Paul Turek, sees this as a men’s‑health breakthrough. Because partners often drag men in for fertility workups, a semen analysis becomes a rare moment to catch metabolic disease, diabetes, cancer risk, or lifestyle issues early. He notes that the semen analysis is a “poker hand” that can point to specific exposures, and now also to longevity. This aligns with Peter Attia’s Medicine 3.0 philosophy, treating fertility as a canary in the coal mine. Turek hopes this data will spur insurers and public health efforts to use semen analysis as a routine health metric, not just an infertility test.

The guest says he ‘loved it’ and has used it in a couple dozen men. It produces physiologic testosterone levels (400‑700 ng/dL) with twice‑daily dosing, far fewer side effects than injectables, and rarely causes polycythemia. However, about 10% of men don’t respond, and twice‑a‑day dosing is a compliance hurdle. Peter Attia notes a practical challenge: when to draw blood, because the half‑life means a morning trough level may look hypogonadal even though daytime levels are adequate. Still, the drug fills a niche for men who want TRT without losing fertility, as it does not suppress LH/FSH as aggressively as weekly injections.